"Anti-Allergic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)
| Descriptor ID |
D018926
|
| MeSH Number(s) |
D27.505.954.016
|
| Concept/Terms |
Anti-Allergic Agents- Anti-Allergic Agents
- Agents, Anti-Allergic
- Anti Allergic Agents
- Anti-Allergy Drugs
- Anti Allergy Drugs
- Drugs, Anti-Allergy
- Antiallergy Agents
- Agents, Antiallergy
- Antiallergic Drugs
- Drugs, Antiallergic
- Antiallergics
- Anti-Allergics
- Anti Allergics
- Antiallergic Agents
- Agents, Antiallergic
|
Below are MeSH descriptors whose meaning is more general than "Anti-Allergic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Allergic Agents".
This graph shows the total number of publications written about "Anti-Allergic Agents" by people in this website by year, and whether "Anti-Allergic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 3 | 0 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 10 | 6 | 16 |
| 2018 | 14 | 7 | 21 |
| 2019 | 9 | 2 | 11 |
| 2020 | 2 | 3 | 5 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Anti-Allergic Agents" by people in Profiles.
-
Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19. Dermatol Ther. 2021 11; 34(6):e15111.
-
Angioedema: differential diagnosis and acute management. Postgrad Med. 2021 Sep; 133(7):765-770.
-
Anti-Inflammatory, Antiallergic, and COVID-19 Main Protease (Mpro) Inhibitory Activities of Butenolides from a Marine-Derived Fungus Aspergillus terreus. Molecules. 2021 Jun 02; 26(11).
-
Providing open-label placebos remotely-A randomized controlled trial in allergic rhinitis. PLoS One. 2021; 16(3):e0248367.
-
2020: The year in review. J Allergy Clin Immunol. 2021 02; 147(2):495-497.
-
The impact of COVID-19 pandemic on the management of patients with chronic urticaria: An observational two-center study from Turkey. Dermatol Ther. 2021 Jan; 34(1):e14652.
-
COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases. Int J Dermatol. 2021 Feb; 60(2):253-254.
-
Contact dermatitis due to masks and respirators during COVID-19 pandemic: What we should know and what we should do. Dermatol Ther. 2020 Nov; 33(6):e14528.
-
Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post-COVID syndrome? Drug Discov Ther. 2020 Nov 04; 14(5):259-261.
-
Comment on "Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab". Int J Dermatol. 2020 11; 59(11):1417-1418.